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The hypothesis that cells become malignant through a  multistep process has 
been developed from studies on chemically induced tumors (1) and is supported 
by the demonstration that multiple oncogenes are required to induce malignancy 
in vitro (2). Malignant melanoma is a spontaneous human tumor in which clinical 
and histopathologicai criteria can be used to define a series of proliferative lesions 
that apparently constitute different steps in  the evolution from melanocyte to 
malignant melanoma (3). These alterations in growth pattern occur sequentially 
and appear focally within the respective preceding lesion. It would be of great 
value to know whether discrete successive steps in the development of melanoma 
can be correlated with changes in the expression of distinct molecules. Since skin 
lesions  with  altered  growth  of  pigment  cells  can  be  easily  recognized  and 
removed, one approach to this question is to use monoclonal antibodies (mAb) ~ 
(4) as probes on histological sections of such lesions. In the study reported here, 
a  series  of benign  and  malignant  melanocytic lesions  were  examined  using a 
panel of mAbs reactive with malignant melanoma. Two antigens were identified 
that  appear  to  be  differentially expressed  on  malignant  melanoma and  their 
nonmalignant precursor lesions. 
Materials and Methods 
Tissues and  Cells.  Cells  were  isolated  from  lymph  node  metastases  of malignant 
melanomas by  mincing the  tissues  in  phosphate-buffered saline  (PBS), pH  7.2.  The 
released cells were washed twice with PBS and stored at -70°C in RPMI 1640 containing 
20% fetal calf serum (FCS) and 10% dimethylsulfoxide (DMSO). 
Peripheral blood mononuclear cells (PMC)  were isolated from peripheral  blood by 
Ficoll-Hypaque centrifugation and phytohemagglutin in (PHA) blasts examined after 5 d 
of stimulation. Red cells were prepared  from the  Ficoll  pellet and granulocytes were 
obtained by lysing the red cells with 0.15  M NH4CI containing 1 mM EDTA. Tissues 
were frozen immediately after surgical removal in isopentane precooled in liquid nitrogen 
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or directly in liquid nitrogen, and stored at -70°C. The melanoma cell line Mel Ei was 
established in our laboratory (5). All cells were maintained in RPMI 1640 containing 10% 
FCS and 1 mM sodium pyruvate. 
Chemicals.  Where not otherwise stated, chemicals were purchased from Sigma Chem- 
ical Co., St. Louis, MO. 
Antibodies.  mAb 601-13-17 (IgG  1) was obtained from M. Herlyn, The Wistar Institute, 
Philadelphia (6), and mAb DA6.231  (IgG 1) was obtained from K. Guy, MRC Clinical and 
Population Cytogenetics Unit, Western General Hospital, Edinburgh (7). Both antibodies 
are directed against nonpolymorphic determinants on human Ia-like antigens. The hybri- 
domas producing mAb BBM. 1 (IgG2b) specific for ~-microglobulin (8) and mAb 5E9 
(IgGl) that  recognizes the  transferrin  receptor (9)  were  obtained from the  American 
Type Culture Collection (ATCC),  Rockville, MD.  mAb 96.5  (IgG2a, obtained from I. 
Hellstr6m, Fred Hutchinson Cancer Research Center, Seattle) defines a 07 kD glycopro- 
tein that was shown by iron-binding studies and protein sequence analysis to be related to 
transferrin  (10).  MPC11  is  a  murine  myeloma cell  line  secreting  IgG2b of unknown 
specificity, mAb S 1 and $2 (both IgM) are directed against polymorphic determinants on 
human Ia-like molecules (11). 
Fusion  Procedure  and  Screening  of Hybrids.  In  fusion  P,  a  BALB/c  female  mouse 
received 1.5 ×  107 fresh tumor cells from patients ZV and GO intraperitoneally together 
with BordeteUa pertussis adjuvant.  3 d  later, one-third of the spleen was fused with .5  × 
107  P3  ×  63-Ag8.653  myeloma cells  using standard  procedures  (12).  The  cells were 
divided among 864  200-#1  culture  wells  containing  HAT (hypoxanthine,  aminopterin, 
thymidine) medium and mouse peritoneal macrophages. Supernatants of hybrids were 
screened by the ~/-galactosidase  cytoimmunoassay described previously (13).  Hybridomas 
were cloned by limiting dilution. 
257  hybrids  were  initially  screened  for  binding  on  single-cell  suspensions  of  the 
immunizing tumors and PMC (normal and PHA stimulated) from the tumor patients and 
normal  individuals.  The  seven  antibodies  that  reacted  in  this  context  only  with  the 
melanoma cells were cloned.  On the basis of the pattern observed in tissue sections of 
melanomas containing normal skin,  1 antibody (mAb P3.58, IgM) of the 95 that bound 
to the immunizing tumors was chosen for further studies. 
lmmunohistochemistry.  8-#m-thick sections were dried overnight at 40 o  C and processed 
without fixation. Sections that were not used the same day were stored at -70°C. After 
blocking for  1  h  with  PBS-FCS  and  100  ttg/ml  normal  rabbit  Ig,  the  sections  were 
incubated for 1.5 h in mAb, followed by three washings in PBS, each for 5 min. Peroxidase- 
conjugated rabbit anti-mouse Ig (Dakopatts, Copenhagen) was diluted  1:50 in PBS-FCS 
and added for 1 h. (To remove activity against human serum proteins, 50 #l/ml of pooled 
human serum was added to each antiserum stock, at least 1 d  before the first use.) The 
sections were washed three times, fixed for 5 min with 0.07% glutardialdehyde in PBS, 
washed again, and stained for 20-30 min with a solution of 0.07 mg 3-amino-9-ethylcar- 
bazol/ml PBS and 0.003% H202. The carbazol was initially dissolved in DMSO at a  1:30 
dilution.  Counterstaining  was  performed  in  Mayer's hemalum  for <-20  s.  Finally  the 
sections were embedded in Kaiser's glycerol gelatin (E.  Merck AG, Darmstadt, Federal 
Republic of Germany [FRG]). 
Localization of staining was  improved using  !yophilized tissue  sections treated  with 
acetone  and chloroform,  each  for  10  min.  Sensitivity was  considerably  increased  by 
incubating mAb-treated sections first with a rabbit antiserum against mouse Ig, then with 
a swine antiserum against rabbit Ig (both peroxidase conjugates; Dakopatts). Both antisera 
were diluted  1:30 in PBS, pH 7.8, containing 20% human serum, and incubated for 30 
rain (14). Tissue sections were blocked only in PBS-FCS. 
mAb BBM. 1, S1, and $2, and the tissue culture supernatant of the mouse myeloma 
line,  MPC11,  served  as controls.  All  antibodies  were  used as undiluted  tissue  culture 
supernatants dialyzed against PBS. 
Immunoprecipitation.  Mel Ei melanoma cells were surface iodinated using the glucose 
oxidase-lactoperoxidase method as described (15). Cells were lysed (5 x  107/ml) in PBS 
containing 18 mM taurocholic acid, 2 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM 368  IN  SITU  ANTIGEN  EXPRESSION  ON  MELANOMA AND  NEVUS 
benzamidine hydrochloride, and  200  U/ml  trasylol (Bayer AG,  Leverkusen, FRG), pH 
8.0 (lysing buffer) for 30 min at 4°C. The nuclei were removed by centrifugation and the 
lysate was precleared by incubation  with horse serum conjugated to Sepbarose CL-4B. 
To prepare immunosorbents, 40 #i protein A-Sepharose CL-4B were incubated with 0.5 
ml of a  1:10 dilution of rabbit anti-mouse IgM (Nordic Lab., Tilburg, The Netherlands) 
in PBS pH 8.0, washed, and incubated with 15 ml of tissue culture supernatant containing 
mAb. Precleared lysates were incubated with the immunosorbents, with rotation, for 12 
h  at  4°C.  The  bound  immune  complexes were  eluted  by  boiling  in  sodium  dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (with or without 2- 
mercaptoethanol) and analyzed on a  10% SDS-PAGE (16).  Fixed, stained, and dried gels 
were exposed to  Kodak XAR-5  film at  -70°C  with an  intensifying screen.  Molecular 
weight markers (CFA.626) were obtained from Amersham International,  Buckingham- 
shire, England. 
Western Blotting.  The  gp75  antigen  was isolated  from a  lymph  node  metastasis of 
malignant melanoma (DAF) by incubation of a precleared lysate prepared from 1 g tissue 
(homogenized  in  lysing buffer) with  mAb  15.75  bound  to  Sepharose-protein  A.  The 
antigen  was eluted by boiling in  SDS sample buffer and separated on  10%  SDS-PAGE 
under  reducing  conditions.  Separated proteins  were electrophoretically transferred  to 
nitrocellulose  membranes (BA 85;  Schleicher & Sch/ill,  Dassel,  FRG) as described (17, 
18). The filters were incubated with mAb 15.75 or control supernatant (myeloma MPC 11) 
followed by peroxidase-conjugated rabbit anti-mouse Ig (Dakopatts). Bound antibody was 
visualized with the addition ofa substrate solution of 1.26 mM 0-dianisidine hydrochloride, 
15.3 mM sodium nitroferricyanide, and 0.007%  H~O2. 
Results 
Characterization of Antigens Recognized by mAb  15. 75 and P3.58 and Analysis of 
Their Expression on Fresh Tissues.  As previously reported (5), mAb 15.75 defines 
a  75,000  (75  K)  tool  wt  glycoprotein  expressed  on  the  surface  of  human 
melanoma cell lines. As shown by Western blot analysis (Fig.  1), a  molecule with 
the same molecular weight was immunoprecipitated from homogenates of a fresh 
metastatic melanoma.  12 of 15 melanomas examined in tissue sections expressed 
FIGURE  1.  Western blot of gp75 antigen  isolated from melanoma metastasis DAF. Immu- 
noprecipitation,  SDS-PAGE, and blotting are described in Materials and Methods. Nitrocel- 
lulose filters were incubated with mAb 15.75 (A) or control MPC11 myeloma (B), followed by 
peroxidase-coupled rabbit anti-mouse Ig. The bands observed in both lanes at 56, 43, and 25 
tool wt are from the antibody  15.75 used in the immunoprecipitate. HOLZMANN ET  AL.  369 
gp75 as determined by immunoperoxidase staining with mAb 15.75, whereas no 
reactivity was observed with a variety of other carcinomas and benign prolifera- 
tive lesions (Table I).  No reactivity was observed with normal structures of the 
skin  (epidermis,  hair  follicles,  sweat glands,  sebaceous glands),  intestine,  liver, 
and  nerves.  Blood  cells  (red  cells,  granulocytes,  normal  and  PHA-stimulated 
mononuclear cells) and bone marrow cells from seven normal transplant donors 
also showed no reactivity (Table I). 
From a surface-iodinated melanoma cell line, mAb P3.58 immunoprecipitated 
proteins  with  an  approximate  molecular  weight  of 89  K  under  nonreducing 
conditions, and 93 K under reducing conditions (Fig. 2). In histological sections, 
mAb P3.58 reacted with  13 of 15 melanomas and 3 of 16 carcinomas tested. In 
contrast to the melanomas,  all three positive carcinomas of the gastrointestinal 
tract contained only 5-10%  positive tumor cells, much less than  seen in any of 
the melanomas. No reactivity was observed with several other tumors and benign 
proliferative lesions, nor with normal  structures of the skin,  intestine,  liver, or 
nerves (Table I). Occasional positive reactions with blood vessel endothelia were 
observed, but no correlation  could be made  to a  certain  type of blood vessel. 
Blood cells and  bone marrow  cells from  seven normal  transplant donors were 
negative (Table I). 
Comparison of Antigen Expression on Melanomas and Nevi.  15 malignant  mel- 
anomas,  both primary tumors (superficial  spreading  and nodulary  melanomas) 
and metastases, and 21 nevi (19 normal hyperplastic nevi and 2 nevi with cytologic 
atypia) were  investigated  for the  expression  of five different  surface antigens 
defined by mAb. 
12 out of 15 melanomas tested were positive with both mAb 15.75 and P3.58. 
FIGURE 9.  Autoradiogramm of immunoprecipitates from the surface-iodinated melanoma 
cell line Mel Ei. Samples were run on a 10% SDS-PAGE. (A) molecular weight markers, (B) 
antigen precipitated by mAb P3.58, reduced, (C) molecules  precipitated by rabbit anti-mouse 
IgM, reduced, (D) antigen precipitated by mAb P3.58, nonreduced, (E) molecules  precipitated 
by rabbit anti-mouse lgM, nonreduced. 370  IN. SI.TU ANTIGEN EXPRESSI.ON ON  MELANOMA AND  NEVUS 
TABLE  I 
Reactivity of mAb With Tumors and Normal Tissues 
Tissue  gp75*  p89' 
Melanomas  12/15!  13/15 
Carcinomas 
Breast  0/7  0/7 
Stomach  0/1  1  / 1 
Intestine  0/2  2/2 
Liver  0/1  0/1 
Adrenal cortex  0/1  0/1 
Thyroid gland  0/1  0/1 
Basal cell  0/3  0/3 
Neuroblastoma  0/1  0/1 
Fibrosarcoma  0/1  0/1 
Nevi  1/21  2/19 
Goiter  0/2  0/2 
Neurofibroma  0/1  0/1 
Fibroadenoma  0/1  0/1 
(breast) 
Bone marrow  0/7  0/7 
Blood cells  0/5  0/5 
Liver  0/2  0/2 
Intestine  0/3  0/3 
Reactivity was determined  by evaluation of immunoperoxidase staining 
of tissue sections as described in Materials and Methods. 
* Defined by mAb 15.75. 
* Defined by mAb P3.58. 
0 Number  of positive samples per number tested.  Peripheral nerves and 
blood vessels that were observed  in many tissues showed no reactivity. 
Occasional reactivity of mAb P3.58 with endothelial cells was observed 
(see text). 
mAb P3.58  reacted with one additional  melanoma  (Table  II).  Both antibodies 
recognized  only a  subpopulation  of tumor cells,  which varied between  10 and 
50%  for mAb  15.75,  and  20 and  80%  for P3.58  (Fig.  3,  a and c).  Analysis of 
sequential sections indicated that the positive reactivity was confined to discrete 
three-dimensional  nests  of tumor  cells.  Reactivity  of both  antibodies  sharply 
outlined the individual cells (Fig.  3, a and c). This staining pattern is consistent 
with the location of the antigens on the cell surface. That both the gp75 and the 
p89  antigen  are  products  of the  melanoma  cells  themselves  is  supported  by 
studies on cloned melanoma cell lines in vitro. Both antigens are located on the 
surface  of these  cells,  as  demonstrated  by  immunofluorescence  staining  and 
labeling of the molecules  by surface iodination.  In addition,  both antigens are 
labeled  by  incorporation  of radioactive  amino  acids  (Fig.  2;  reference  5  and 
unpublished  data).  Melanoma  cells  invading  epidermis  or  hair  follicles  were 
consistently negative for both antigens.  No distinction, by reactivity with either 
antibody, could be made between different histological types of melanomas nor 
between primary or metastatic tumors. In contrast, the majority ofnevi examined 
were negative  with both antibodies (Fig.  3, b and d).  Brown granules on some 
nevus  cells represent  typical  melanin  deposits.  Of 21  normal  hyperplastic  and 
atypical nevi, only a single junctional nevus showed reactivity with both antibod- HOLZMANN  ET  AL. 
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Reactivity of mAb With Melanomas 
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Melanomas  gp75*  p89"  Ia-like*  p970 
Primary tumors 
SSM ! 
2316,  LI  ~  -  -  +  + 
2199,  LII  +  +  +  + 
2166,  LIII  +  +  +  + 
2183,  LIII  +  +  +  NT** 
2202,  LIII  +  +  +  + 
2215,  LIII  -  -  +  - 
2234,  LIII  -  +  +  + 
GRU, LIV  +  +  +  + 
NM  ~ 
2242,  LIV  +  +  +  + 
2164,  LIV  +  +  +  NT 
2189,  LIV  +  +  +  NT 
HUK, LV  +  +  +  NT 
Metastases 
Lymph node 
DAF  +  +  +  NT 
PET  +  +  +  + 
Skin, 2273  +  +  +  + 
* See Table I. 
* Defined by mAb 691-13-17. 
0 Defined by mAb 96.5. 
u Superficial spreading melanoma. 
Level of tumor invasion according to Clark (41). 
** Not tested. 
Nodulary melanoma. 
ies. mAb P3.58 reacted with one additional intradermal nevus (Table III). Using 
the more sensitive immunohistochemical technique described in  Materials and 
Methods, we did not observe any difference in the staining pattern ofmAb 15.75 
and P3.58 on melanomas, nor reactivity with nevi. 
mAb 96.5, directed against the transferrin-related molecule p97, reacted with 
9  of  10  melanomas tested  and  16  of  17  nevi  (Tables  II  and  III),  which  is 
consistent with previous reports (19). In addition, we observed staining of sweat 
glands and the basal cell layer of hair follicles. 
Both melanomas (three of three) and nevi (seven of eight) showed expression 
of the transferrin receptor as defined by mAb 5E9 (Table III). Strong reactivity 
was also  observed with  epidermis,  hair  follicles,  sweat glands,  and  sebaceous 
glands. Smooth muscle, blood vessels, and connective tissue were found to be 
negative. 
Using two mAb against monomorphic determinants on human Ia-like antigens, 
all melanomas examined expressed these molecules (Table II). Expression of Ia- 
like  antigens  was  also  observed  on  nevus  cells  in  all  nevi  (Table  III).  The 
Langerhans cells in the epidermis showed the characteristic strong expression of 
Ia-like antigens (20) and similar cells were observed in the dermis between the 
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FIGURE 3.  Immunoperoxidase staining of melanomas and nevi with different mAb. X  160 
(mAb P3.58),  X  160 (mAb 15.75).  (A) melanoma GRU,  mAb  15.75, (B) intradermal nevus, 
mAb 15.75, (C) melanoma GRU, mAb P3.58, (D) intradermal nevus, mAb P3.58. HOLZMANN  ET  AL.  373 
TABLE  III 
Reactivity of mAb With Nevi 
Nevi  gp75*  p89"  p97"  TRt  Ia-like*  la-like! 
Common acquired nevi 
Junctional  1/41  1/4  3/3  NT  q  3/3  NT 
Compound  0/5  0/4  3/4  3/4  5/5  4/4 
Intradermal  0/9  1/8  8/8  4/4  9/9  4/4 
Spindle cell  0/1  0/1  1  / 1  NT  1  / 1  NT 
Nevi with cytologic atypia 
Atyp Mel Hyp**  0/1  0/1  1/1  NT  1/1  NT 
Atyp Nev Lea  ~  0/1  0/1  NT  NT  1/1  NT 
* See Table I and lI. 
*  Transferrin receptor defined by mAb 5E9. 
! Defined by mAb DA6.231. 
! See description of data in Table I. 
1 Not tested. 
** Atypical melanocytic hyperplasia. 
¢* Atypical nevoid lentigo. 
Discussion 
The melanocyte lineage provides a  unique system for the study of changes 
occurring during the development of spontaneous solid tumors in man (3, 30). 
While  normal  melanocytes are  scattered  through  the  basal  cell  layer  of the 
epidermis,  the  benign  proliferation  of melanocytes and  their  organization  in 
clusters gives rise to a nevus. The majority of melanomas are thought to develop 
through the malignant transformation of melanocytes in preexisting nevi (3, 21). 
Clark  et al.  (3)  recently described the evolution of malignant melanoma as a 
sequence of several alterations of melanocyte growth, beginning with the focal 
proliferation of benign cells (common aquired nevus) and leading finally to the 
metastatic melanoma. Thus, the hypothesis of multistep tumorigenesis, originally 
developed in experimental tumor systems (1, 2), is supported by in vivo investi- 
gations on a spontaneous human solid tumor. 
Numerous mAb have been produced against human malignant melanoma (5, 
22-27). While several of these melanoma-associated antigens are not detectable 
on melanocytes (19, 28-30), all markers examined are expressed on benign nevi 
as well as melanomas (19, 26, 28, 29, 31). The focus of this study was to define, 
on a molecular basis, differences between the clearly benign (but activated) and 
the clearly malignant phenotypes of melanocytes. To this end,  we looked for 
mAb  that  could  distinguish  between  common acquired  nevi  and  malignant 
melanoma. 
Malignant melanomas have been reported to express Ia-like antigens (32, 33), 
transferrin receptor (34), and the transferrin-related molecule, p97 (10). While 
Ia-like antigens were not detected on skin melanocytes either in situ (20) or after 
short-term culture (30) (adult and fetal), they have been reported on nevus cells 
both in short-term culture (31) and in situ (28). In the present study, using two 
different mAb directed against monomorphic determinants on human  Iaolike 
antigens, all  nevi were  found to contain positive nevus cells and a  substantial 
fraction of cells expressing the transferrin receptor. Since the expression of the 
transferrin receptor has been shown (9, 34) to be associated with cell proliferation 374  IN  SITU ANTIGEN EXPRESSION ON  MELANOMA AND NEVUS 
and activation, these observations confirm the view that nevi contain populations 
of activated and proliferating pigment cells. As nevi are essentially benign lesions, 
neither  the  expression  of transferrin  receptor  nor  of Ia  antigens  mark  the 
transition to the transformed state. 
In contrast, the two antigens, gp75 and p89, as defined by mAb  15.75  and 
P3.58, respectively, appear to be differentially expressed on malignant melano- 
mas and their nonmalignant precursor lesions.  Whereas  12  of 15  melanomas 
showed reactivity with both antibodies, only 1 of 21  nevi was reactive. Analysis 
of serial sections confirmed that each antibody reacted only with a subpopulation 
of tumor cells, as reported with  mAb directed to  other antigens  (29,  35).  It 
appears that the tumor cell populations recognized by each antibody are usually 
not overlapping.  The  absence  of these  antigens on  the activated nevus cells 
suggests that they are correlated with the appearance of the malignant phenotype 
of melanocytes, although the correlation is not absolute, since one nevus reacted 
with both mAb 15.75 and P3.58, and one additional nevus only with mAb P3.58. 
Whether the molecules defined by these two mAb are required for malignant 
transformation cannot be answered by antibody binding, and will require further 
biochemical and molecular biological studies. However, it is possible that changes 
usually connected with  malignant  transformation appear  on  morphologically 
nonmalignant tissue, if other events necessary for transformation are missing. 
Since this study focused on histologically normal nevi, the antigen expression of 
intermediate phenotypes like dysplastic nevi requires further investigation. 
Recent observations on oncogenes indicate that malignant cells may indeed 
differ from  their  normal  counterpart,  not  only by  quantitative  or  temporal 
variation in the expression of certain molecules (36,  37), but in the expression 
of structurally altered molecules (38,  39).  Thus,  while many quantitative and 
qualitative differences are detected on the mRNA level using a cDNA subtraction 
technique (40), discrete structural alterations may best be defined by mAb. The 
selection of mAb for differential reactivity on malignant vs. benign hyperplastic 
lesions of the same lineage may be a useful approach in detecting such molecules. 
Summary 
Monoclonal antibodies (mAb) were selected for differential binding to sections 
of freshly frozen  biopsy  material  of human  malignant  melanomas and  their 
precursor lesions, the melanocytic nevi.  Both melanomas and normal nevi ex- 
pressed human Ia-like antigens, transferrin receptor and the transferrin-related 
molecule p97. In contrast, only 1 nevus of 21 tested expressed both glycoprotein 
gp75, defined by mAb 15.75, and protein p89, defined by mAb P3.58, whereas 
12 of 15  melanomas tested expressed both antigens, mAb P3.58 reacted with 
one additional melanoma and one nevus. The expression of these two molecules 
therefore appears to be correlated with the appearance of the malignant phe- 
notype of melanocytes. 
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